

		1956.03			
	1980.01				



--	--	--	--	--	--

	1956	3			
			1980	1	1989
		1995			
1996			1998		2011
		2003	"		"
		2007		2009	"
"	2011				
1976.09 — 1979.07					
1986.09 — 1989.07					
1992.09 — 1995.07					
1. Z.Y. Zh, Y.Q. Mu, F.X.Zhao . Association of CYP1B1 gene polymorphisms and the positive expression of estrogen and estrogen with endometrial cancer risk[J]. European Journal of Gynaecological Oncology, 2011, 32(2): 188-191. (SCI).					
2. Fuxi Zhao, Jian Wang, Runhua Liu, et al. Quantification and application of the placental epigenetic signature of the RASSF1A gene in maternal plasma[J]. Prenat Diagn, 2010, 30(8): 778-782. (SCI).					
3. Fuxi Zhao, Yuanyuan Zhang, Runhua Liu, et al. Effect of blockage of costimulatory signal on murine abortion-prone model [J]. J Chi Med, 2007,120(14): 1247-1250. (SCI).					

4. Fuxi Zhao, Yuanyuan Zhang, Runhua Liu, et al. Effect of CD86 blockage on the expressions of TGF- 1,MMP-9,TIMP-3 and PAI-1 proteins and outcome of pregnancy in murine abortion-prone model [J].J Microbiol Immunol, 2006, 4(2):137-145.
5. RASSF1A
[J] 2014 31 1 25-28
6. [J] 2014 17 1 10-13
7. SERPINB5
[J] 2013 28 30 5042-5045
8. [J] 2013 21 1 13-15
9. CYP17 [J] 2013 40 13 2502-2504
10. / [J] 2013 29 5 763-766
11. CYP1B1 A119S
[J] 2013 28 9 1489-1491
12. [J] 2013 28 8 1306-1308
13. HPV [J] 2012 39 19 4962-4963 4965
14. E cadherin
HPV [J] 2012 28 11 1006-1008
15. CD4+CD25+Treg
Foxp3 [J] 2012 28 7 595-599
16. PCR maspin
2012 20 2 22-26
17. TSA CD4+CD25+ T
2012 20 5 21-23
18. T
2012 7 6 5-6
19. RASSF1A
[J] 2011 31 4 347-351
20. DNA [J] 2011 14(2) 84-86
21. [J]. , 2011 6 1050-1051+1054
22. RASSF1A
[J] 2010 27 1 73-76
23. TLR4 NF- B TNF- NAC
[J] 2009 25 4 328-332
24. N- (NAC)
[J] 2009 29 5 273-278
25. NAC TLR4 NF- B
2009 17 5 267-271.

26. -kappa B
-9 mRNA 2009 18 17 1984-1986+2046
27. Caspase-3 laminin B
[J] 2007 2 136 83-86.
28. MMP-9/TIMP-3
[J] 2007 27 1 26-30.
29. CD86 TGF-1 MMP-9/TIMP-3 PAI-1
1 [J] 2007 27 3 217-221.
30. Caspase-3 laminin B PAI-1
[J] 2007 22 28 3993-3996.
31. TGF- 1 PAI-1
[J]. ,2007,23(5):438-442.
32. T [J]
2006 17 3 184-187.

1. Juncheng G, Fuxi Z , Runhua L, et al. Prevalence and type distribution of human papillomavirus infection in women from Datong, China. *Scand J Infect Dis*, 2010; 42: 72-75 (SCI).
2. Yaqin Mu, Runhua Liu, Fuxi Zhao . Analyses of Bcl-2, Survivin, and CD44v6 expressions and human papillomavirus infection in cervical carcinomas [J]. *Scand J Infect Dis*, 2007, 39(5): 441-448 (SCI).
3. Fuxi Zhao Jie Yan Xiyang Wang et al. Study on relationship between microsatellite alterations of *RASSF1A* gene and the development of cervical carcinoma [J]. *Chi J Can Res*, 2007; 19(1): 45-51. (SCI).
4. Fuxi Zhao, Juncheng Guo, Ke Cui, et al. Cyclin E, p16^{ink4} and Ki67 overexpression as possible diagnostic markers in HPV-related cervical neoplasial cell [J]. *Infect Dis Clin Pract*, 2006, 14 154-157.
5. Fuxi Zhao, Yaqin Mu, Juncheng Guo, et al. Expression of Bcl-2 and Survivin in uterine cervical carcinogenesis and correlation between the expression and infection of HPV_{16/18} [J]. *J Microbial Immunol*, 2005, 3(4): 246-253.
6. Zhao Fuxi, Guo Juncheng, Ke Cui, et al. Significance of Cyclin E p16^{ink} Ki67 overexpression in cervical exfoliated cell specimens for the primary screening of HPV-related cervical carcinoma [J]. *J Microbial Immunol*, 2004, 12(4): 260-264.
7. Fuxi Zhao, Yaqin Mu, Juncheng Guo, et al. The expression of Bcl-2 Survivin CD44v6 and the correlation between them and apoptosis and HPV_{16/18} in uterine cervical carcinogenesis [C]. *Proceeding of 2005 ISAV, Beijing China, Oct 10-13, 2005*.
8. Fuxi Zhao, Lee Kun, Jingyi Si. Molecular and cellular biology study on relationship among HPV protooncogene and antioncogene in the carcinogenesis of cervix carcinoma [C]. 4th congress Asia Pacific association of virologists " v e a n J " a ao

34. cyclin E Ki67 [J]
2006 13 9 666-668.
35. Cyclin E p16ink4 ki67 HPV_{16/18}
[J] 2005 19 2 138-141.
36. HPV₁₆ HTERT
P21^{Waf} ki67 [J] 2005 19 4 370-374.
37. hTERT [J] HPV₁₆
2005 12 5 388-391.
38. HPV₁₆
P21^{waf} ki67 [J] 2005 32 10 1284-1286.
39. Cyclin E p16ink4 ki67
[J] 2005 32 4 307-309.
40. TNF [J]
1997 9 1 33-34.
41. HBV [J]
1996 5 3 14-16.
42. HPV [J] 1996 23
11 769-773.
43. PCR [J]
1995 7 2 19-20.
44. P53 LOH HPV [J]
1995 7 4 21-25.
45. PCR/RFLP P53 [J]
1995 24 6 381.
46. C-myc H-ras HPV [J]
1995 15 5 347-351.
47. PCR HPV DNA
[J] 1994 8 4 40-44.
48. HPV18 HPV16
[J] 1994 16 2 102-105.
49. PCR RFLP
[J] 1993 13 5 320-322.
50. HBV [J].
1993 6 3 368-369.
51. [J]
1993 6 3 78-81.
52. [J]
1993 12 2 100.
53. DIA McAbELISA PAGE [J]
1993, 7 2 188-190.
54. [J]
1992 4 2 14-17.
55. A [J] 1991 3
5 28.
56. HBV DNA [J]

1. 1999
2. 2004 2
3. 5 2004 4
4. 2005 9
5. 2 2007 9
6. " "
7. 2009 7 2009 9
8. 2009 12
9. 2011 1
10. 2013 3
11. 2014 1

o

1. CD4+Foxp3+ T
[2012]46 20 2012
2. Foxp3 81170621
65 2012-2015
3. HPSE
2010021036 8 3 2010-2012
4. Foxp3
20101024 10 2010
5. C-73 2009-2011
6. 2008 -2012 10
7. RASSF1A
10 2009 -2013
1. TORCH
20080311072 5 2008-2010
2. RNA CYP1B1
[2008]021046 4.8 1.8 2008-2010

10. 2001

11. P⁵³ C-myc H-ras HPV 1996

12. 1999

13. 2004

14. 2003